Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulation

References

• Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86. doi:10.1002/ijc.29210. PMID:25220842.
   PubMed Web of Science ®Google Scholar
• Tommelein J, Verset L, Boterberg T, Demetter P, Bracke M, De Wever O. Cancer-associated fibroblasts connect metastasis-promoting communication in colorectal cancer. Front Oncol. 2015;5:63. doi:10.3389/fonc.2015.00063. PMID:25853091.
   PubMed Web of Science ®Google Scholar
• Herrera M, Islam AB, Herrera A, Martin P, Garcia V, Silva J, Garcia JM, Salas C, Casal I, de Herreros AG, et al. Functional heterogeneity of cancer-associated fibroblasts from human colon tumors shows specific prognostic gene expression signature. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2013;19:5914–26. doi:10.1158/1078-0432.CCR-13-0694. PMID:24052018.
   PubMed Web of Science ®Google Scholar
• Harper J, Sainson RC. Regulation of the anti-tumour immune response by cancer-associated fibroblasts. Semin Cancer Biol. 2014;25:69–77. doi:10.1016/j.semcancer.2013.12.005. PMID:24406209.
   PubMed Web of Science ®Google Scholar
• Pinchuk IV, Beswick EJ, Saada JI, Boya G, Schmitt D, Raju GS, Brenmoehl J, Rogler G, Reyes VE, Powell DW. Human colonic myofibroblasts promote expansion of CD4+ CD25high Foxp3+ regulatory T cells. Gastroenterology. 2011;140:2019–30. doi:10.1053/j.gastro.2011.02.059. PMID:21376048.
   PubMed Web of Science ®Google Scholar
• Gunaydin G, Kesikli SA, Guc D. Cancer associated fibroblasts have phenotypic and functional characteristics similar to the fibrocytes that represent a novel MDSC subset. Oncoimmunology. 2015;4:e1034918. doi:10.1080/2162402X.2015.1034918. PMID:26405600.
   PubMed Web of Science ®Google Scholar
• Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16:582–98. doi:10.1038/nrc.2016.73. PMID:27550820.
   PubMed Web of Science ®Google Scholar
• Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25:719–34. doi:10.1016/j.ccr.2014.04.005. PMID:24856586.
   PubMed Web of Science ®Google Scholar
• Cortez E, Roswall P, Pietras K. Functional subsets of mesenchymal cell types in the tumor microenvironment. Semin Cancer Biol. 2014;25:3–9. doi:10.1016/j.semcancer.2013.12.010. PMID:24412106.
   PubMed Web of Science ®Google Scholar
• Koliaraki V, Pallangyo CK, Greten FR, Kollias G. Mesenchymal Cells in Colon Cancer. Gastroenterology. 2017;152:964–79. doi:10.1053/j.gastro.2016.11.049. PMID:28111227.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Freeman GJ. The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov. 2015;5:16–8. doi:10.1158/2159-8290.CD-14-1397. PMID:25583798.
   PubMed Web of Science ®Google Scholar
• Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138:2073–87e3. doi:10.1053/j.gastro.2009.12.064. PMID:20420947.
   PubMed Web of Science ®Google Scholar
• Jacobs J, Deschoolmeester V, Zwaenepoel K, Rolfo C, Silence K, Rottey S, Lardon F, Smits E, Pauwels P. CD70: An emerging target in cancer immunotherapy. Pharmacology & Therapeutics. 2015;155:1–10. doi:10.1016/j.pharmthera.2015.07.007. PMID:26213107.
   PubMed Web of Science ®Google Scholar
• De Meulenaere A, Vermassen T, Aspeslagh S, Zwaenepoel K, Deron P, Duprez F, Ferdinande L, Rottey S. CD70 Expression and Its Correlation with Clinicopathological Variables in Squamous Cell Carcinoma of the Head and Neck. Pathobiology. 2016;83:327–33. doi:10.1159/000446569. PMID:27389010.
   PubMed Web of Science ®Google Scholar
• Claus C, Riether C, Schurch C, Matter MS, Hilmenyuk T, Ochsenbein AF. CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth. Cancer Res. 2012;72:3664–76. doi:10.1158/0008-5472.CAN-11-2791. PMID:22628427.
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol. 2005;6:1142–51. doi:10.1038/ni1263. PMID:16227984.
   PubMed Web of Science ®Google Scholar
• Rolfo C, Caglevic C, Santarpia M, Araujo A, Giovannetti E, Gallardo CD, Pauwels P, Mahave M. Immunotherapy in NSCLC: A Promising and Revolutionary Weapon. Adv Exp Med Biol. 2017;995:97–125. doi:10.1007/978-3-319-53156-4_5. PMID:28321814.
   PubMed Web of Science ®Google Scholar
• Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14:463–482. doi:10.1038/nrclinonc.2017.43. PMID:28374786.
   PubMed Web of Science ®Google Scholar
• Callahan MK, Postow MA, Wolchok JD. CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. Front Oncol. 2014;4:385. PMID:25642417.
   PubMed Web of Science ®Google Scholar
• Donin NM, Lenis AT, Holden S, Drakaki A, Pantuck A, Belldegrun A, Chamie K. Immunotherapy for the Treatment of Urothelial Carcinoma. J Urol. 2017;197:14–22. doi:10.1016/j.juro.2016.02.3005. PMID:27460757.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372:2509–20. doi:10.1056/NEJMoa1500596. PMID:26028255.
   PubMed Web of Science ®Google Scholar
• Jacobs J, Smits E, Lardon F, Pauwels P, Deschoolmeester V. Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. J Immunol Res. 2015;2015:158038. doi:10.1155/2015/158038. PMID:26605342.
   PubMed Web of Science ®Google Scholar
• Smyrk TC, Watson P, Kaul K, Lynch HT. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer. 2001;91:2417–22. doi:10.1002/1097-0142(20010615)91:12%3c2417::AID-CNCR1276%3e3.0.CO;2-U. PMID:11413533.
   PubMed Web of Science ®Google Scholar
• Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5:43–51. doi:10.1158/2159-8290.CD-14-0863. PMID:25358689.
   PubMed Web of Science ®Google Scholar
• Huijbers A, Tollenaar RA, v Pelt GW, Zeestraten EC, Dutton S, McConkey CC, Domingo E, Smit VT, Midgley R, Warren BF, et al. The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Ann Oncol. 2013;24:179–85. doi:10.1093/annonc/mds246. PMID:22865778.
   PubMed Web of Science ®Google Scholar
• Pure E, Lo A. Can Targeting Stroma Pave the Way to Enhanced Antitumor Immunity and Immunotherapy of Solid Tumors? Cancer Immunol Res. 2016;4:269–78. doi:10.1158/2326-6066.CIR-16-0011. PMID:27036971.
   PubMed Web of Science ®Google Scholar
• Mukaida N, Sasaki S. Fibroblasts, an inconspicuous but essential player in colon cancer development and progression. World J Gastroenterol. 2016;22:5301–16. doi:10.3748/wjg.v22.i23.5301. PMID:27340347.
   PubMed Web of Science ®Google Scholar
• Ortiz-Cuaran S, Swalduz A, Albaret MA, Menetrier-Caux C, Haddad V, Paré A, De Souza G, Morel AP, Pérol M, Caux C, et al. Abstract 2320: CD70 immune checkpoint ligand is associated with the epithelial-to-mesenchymal transition in non-small cell lung cancer. Cancer Res. 2016;76:2320 -. doi:10.1158/1538-7445.AM2016-2320.
   Web of Science ®Google Scholar
• Pich C, Sarrabayrouse G, Teiti I, Mariame B, Rochaix P, Lamant L, Favre G, Maisongrosse V, Tilkin-Mariame AF. Melanoma-expressed CD70 is involved in invasion and metastasis. Br J Cancer. 2016;114:63–70. doi:10.1038/bjc.2015.412. PMID:26671750.
   PubMed Web of Science ®Google Scholar
• Ge H, Mu L, Jin L, Yang C, Chang Y, Long Y, De Leon G, Deleyrolle L, Mitchell DA, Kubilis PS, et al. Tumor Associated with CD70 Expression is Involved in Promoting Tumor Migration and Macrophage Infiltration in GBM. International Journal of Cancer. 2017;141:1434–44. doi:10.1002/ijc.30830. PMID:28612394.
   PubMed Web of Science ®Google Scholar
• Mashita N, Yamada S, Nakayama G, Tanaka C, Iwata N, Kanda M, Kobayashi D, Fujii T, Sugimoto H, Koike M, et al. Epithelial to mesenchymal transition might be induced via CD44 isoform switching in colorectal cancer. J Surg Oncol. 2014;110:745–51. doi:10.1002/jso.23705. PMID:24975268.
   PubMed Web of Science ®Google Scholar
• Huh JW, Kim HR, Kim YJ, Lee JH, Park YS, Cho SH, Joo JK. Expression of standard CD44 in human colorectal carcinoma: association with prognosis. Pathol Int. 2009;59:241–6. doi:10.1111/j.1440-1827.2009.02357.x. PMID:19351367.
   PubMed Web of Science ®Google Scholar
• Jacobs J, Zwaenepoel K, Rolfo C, Van den Bossche J, Deben C, Silence K, Hermans C, Smits E, Van Schil P, Lardon F, et al. Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer. Oncotarget. 2015;6:13462–75. doi:10.18632/oncotarget.3880. PMID:25951351.
   PubMedGoogle Scholar
• Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood. 2006;107:3639–46. doi:10.1182/blood-2005-08-3376. PMID:16403912.
   PubMed Web of Science ®Google Scholar
• deLeeuw RJ, Kost SE, Kakal JA, Nelson BH. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2012;18:3022–9. doi:10.1158/1078-0432.CCR-11-3216. PMID:22510350.
   PubMed Web of Science ®Google Scholar
• Hanke T, Melling N, Simon R, Sauter G, Bokemeyer C, Lebok P, Terracciano LM, Izbicki JR, Marx AH. High intratumoral FOXP3(+) T regulatory cell (Tregs) density is an independent good prognosticator in nodal negative colorectal cancer. Int J Clin Exp Pathol. 2015;8:8227–35. PMID:26339391.
   PubMed Web of Science ®Google Scholar
• Tu JF, Ding YH, Ying XH, Wu FZ, Zhou XM, Zhang DK, Zou H, Ji JS. Regulatory T cells, especially ICOS+ FOXP3+ regulatory T cells, are increased in the hepatocellular carcinoma microenvironment and predict reduced survival. Sci Rep. 2016;6:35056. doi:10.1038/srep35056. PMID:27725696.
   PubMed Web of Science ®Google Scholar
• Zhuo C, Xu Y, Ying M, Li Q, Huang L, Li D, Cai S, Li B. FOXP3+ Tregs: heterogeneous phenotypes and conflicting impacts on survival outcomes in patients with colorectal cancer. Immunol Res. 2015;61:338–47. doi:10.1007/s12026-014-8616-y. PMID:25608795.
   PubMed Web of Science ®Google Scholar
• Lin Y-C, Mahalingam J, Chiang J-M, Su P-J, Chu Y-Y, Lai H-Y, Fang J-H, Huang C-T, Chiu C-T, Lin C-Y. Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer. Int J Cancer. 2013;132:1341–50. doi:10.1002/ijc.27784. PMID:22907255.
   PubMed Web of Science ®Google Scholar
• Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Taflin C, Heike T, Valeyre D, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009;30:899–911. doi:10.1016/j.immuni.2009.03.019. PMID:19464196.
   PubMed Web of Science ®Google Scholar
• Jafarinia M, Mehdipour F, Hosseini SV, Ghahramani L, Hosseinzadeh M, Ghaderi A. Determination of a CD4+CD25-FoxP3+ T cells subset in tumor-draining lymph nodes of colorectal cancer secreting IL-2 and IFN-gamma. Tumour Biol. 2016;37:14659–66. doi:10.1007/s13277-016-5345-y. PMID:27619682.
   PubMedGoogle Scholar
• Clarke SL, Betts GJ, Plant A, Wright KL, El-Shanawany TM, Harrop R, Torkington J, Rees BI, Williams GT, Gallimore AM, et al. CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS One. 2006;1:e129. doi:10.1371/journal.pone.0000129. PMID:17205133.
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Eder R, Kunz-Schughart LA, Andreesen R, Edinger M. Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood. 2004;104:895–903. doi:10.1182/blood-2004-01-0086. PMID:15090447.
   PubMed Web of Science ®Google Scholar
• Ruprecht CR, Gattorno M, Ferlito F, Gregorio A, Martini A, Lanzavecchia A, Sallusto F. Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J Exp Med. 2005;201:1793–803. doi:10.1084/jem.20050085. PMID:15939793.
   PubMed Web of Science ®Google Scholar
• Jeffrey SC, Burke PJ, Lyon RP, Meyer DW, Sussman D, Anderson M, Hunter JH, Leiske CI, Miyamoto JB, Nicholas ND, et al. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug Chem. 2013;24:1256–63. doi:10.1021/bc400217g. PMID:23808985.
   PubMed Web of Science ®Google Scholar
• Owonikoko TK, Hussain A, Stadler WM, Smith DC, Kluger H, Molina AM, Gulati P, Shah A, Ahlers CM, Cardarelli PM, et al. First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. Cancer Chemother Pharmacol. 2016;77:155–62. doi:10.1007/s00280-015-2909-2. PMID:26576779.
   PubMed Web of Science ®Google Scholar
• Silence K, Dreier T, Moshir M, Ulrichts P, Gabriels SM, Saunders M, Wajant H, Brouckaert P, Huyghe L, Van Hauwermeiren T, et al. ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade. mAbs. 2014;6:523–32. doi:10.4161/mabs.27398. PMID:24492296.
   PubMed Web of Science ®Google Scholar
• Goethals S, De Wilde A, Lesage K, Smits E, Pauwels P, Peeters M. Tumorbank@UZA: A Collection of Tissue, Fluid Samples and Associated Data of Oncology Patients for the Use in Translational Research. Open J Bioresour, 2018;5:4. doi:10.5334/ojb.30.
   Google Scholar
• Henry LR, Lee HO, Lee JS, Klein-Szanto A, Watts P, Ross EA, Chen WT, Cheng JD. Clinical implications of fibroblast activation protein in patients with colon cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2007;13:1736–41. doi:10.1158/1078-0432.CCR-06-1746. PMID:17363526.
   PubMed Web of Science ®Google Scholar
• Aftimos P, Rolfo C, Rottey S, Offner F, Bron DD, Maerevoet M, Soria JC, Moshir M, Dreier T, van Rompaey L, et al. Phase 1 dose-escalation study of the anti-CD70 antibody ARGX-110 in Advanced Malignancies. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2017;23:6411–20. doi:10.1158/1078-0432.CCR-17-0613. PMID:28765328.
   PubMed Web of Science ®Google Scholar
• Van Hoorde L, Braet K, Mareel M. The N-cadherin/catenin complex in colon fibroblasts and myofibroblasts. Cell Adhes Commun. 1999;7:139–50. doi:10.3109/15419069909034397. PMID:10427966.
   PubMedGoogle Scholar
• Jesnowski R, Furst D, Ringel J, Chen Y, Schrodel A, Kleeff J, Kolb A, Schareck WD, Lohr M. Immortalization of pancreatic stellate cells as an in vitro model of pancreatic fibrosis: deactivation is induced by matrigel and N-acetylcysteine. Lab Invest. 2005;85:1276–91. doi:10.1038/labinvest.3700329. PMID:16127427.
   PubMed Web of Science ®Google Scholar
• Limame R, Wouters A, Pauwels B, Fransen E, Peeters M, Lardon F, De Wever O, Pauwels P. Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays. PLoS One. 2012;7:e46536. doi:10.1371/journal.pone.0046536. PMID:23094027.
   PubMed Web of Science ®Google Scholar